Report results from Part 1 of Phase 3 GUARD trial of ADX-2191

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 17 Mar 2022
Due: 31 Dec 2022
Delivered: October 2022

Deadline
Met
Late
Not met
Today

What the company said

“Results from Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected in the Second Half of 2022”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2022-03-17
FilingSEC filing index
Deadline as statedin the Second Half of 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2022-ALDX-003453
Cite as https://keptindex.org/c/KI-C-2022-ALDX-003453/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced the results of Part 1 of the Phase 3 GUARD trial in October 2022, which falls within the second half of 2022.

A
Aldeyra Therapeutics, Inc. 10-K filed 2023-03-09 Regulatory filing · published 9 Mar 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint ebbebd71f16e
“In October 2022, we announced results of Part 1 of the GUARD Trial, a two-part, multi-center Phase 3 clinical trial evaluating the efficacy of intravitreal injections of ADX‑2191 versus standard-of-care” ✓ confirmed on the page

Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (8 Mar 2023 to 13 Mar 2023). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +181 days
2 versions

Version 1 · original · stated 17 Mar 2022

Deadline 31 Dec 2022 (“in the Second Half of 2022”) · wording expected
Version 2 · stated 5 Aug 2022

Deadline 30 Jun 2023 (“the first half of 2023”) · wording expected

“Top-line results from the Phase 2 clinical trial of ADX-2191 in patients with retinitis pigmentosa are expected in the first half of 2023.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Phase 3 GUARD trial Part 1 results
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2022-ALDX-003453 · Corrections policy